Opthea solvency in spotlight after ‘negative’ Phase 3 AMD trial result
Melbourne biopharmaceutical firm Opthea has failed to meet the primary end point in a pivotal Phase 3 trial of its...
Melbourne biopharmaceutical firm Opthea has failed to meet the primary end point in a pivotal Phase 3 trial of its...
Researchers in the US are developing lab-grown pig retinal organoids as part of a strategy to combat retinal disease in...
Optometry Australia (OA) is intensifying its election campaign following what it calls “underwhelming responses” from key political parties, warning that...
Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited